DR. S. Banerjee
The Royal Marsden Hospital
Clinical trial locations
In cases where ovarian, fallopian tube or peritoneal cancer has come back (recurrence or relapse) and it has become resistant to platinum-based chemotherapy, new treatment strategies and new drugs are needed to better treat this disease.
About the trial
This study tests a new drug both in combination with a known treatment and alone, in advanced platinum-resistant ovarian cancer.
Atezolizumab (the new drug) is an ‘immunotherapy’ drug that boosts your body's own immune system in a way that may slow down or stop tumour growth.
Bevacizumab, (the known drug), already used against this disease, and given in combination with chemotherapy, is a drug that stops the tumour from growing its own blood vessels, which in turn should slow the growth of the tumour itself.
There is some evidence to suggest that aspirin (acetylsalicylic acid or ASA) may help make these two drugs work better and the addition of aspirin to these drugs is also being tested.
The purpose is to find out whether combinations of atezolizumab with bevacizumab with or without aspirin show activity against ovarian cancer and is safe.
Participants will be split into 3 groups which are: bevacizumab or bevacizumab and atezolizumab and placebo (dummy drug) or bevacizumab and atezolizumab and aspirin. The treatment each group receives is determined by chance using a computer program. The information from these different groups of people will be compared to see which treatment is better.
Who can take part?
This trial is for women that have recurrence of ovarian, fallopian tube or peritoneal cancer that has become resistant to platinum-based chemotherapy.